NFX Nuformix Plc

TIDMNFX

RNS Number : 7136Z

Nuformix PLC

15 January 2024

15 January 2024

Nuformix plc

("Nuformix", the "Company" or the "Group")

Posting of Annual Report and Notice of Annual General Meeting ("AGM")

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that the Annual Financial Report for the 18 months ended 30 September 2023 (the "Annual Financial Report 2023") and the 2024 Notice of AGM are today being posted to its shareholders.

A full pdf version of the Annual Financial Report 2023 together with the Notice of AGM is available for download from the Investor Information section on the Company's website www.nuformix.com .

The Annual Financial Report 2023 will be filed with the Registrar of Companies in due course and copies can be obtained from the Company Secretary, SGH Company Secretaries Limited, 60 Gracechurch Street, London, EC3V 0HR.

The Annual General Meeting will be held on 19 March 2024 at 2.00 pm at the offices of Shakespeare Martineau, 6(th) floor, 60 Gracechurch Street, London, EC3V 0HR.

Enquiries:

 
 Nuformix plc 
 Dr Daniel Gooding, Executive Director      Via IFC Advisory 
 Stanford Capital Partners Limited 
 Tom Price / Patrick Claridge (Corporate 
  Finance)                                  +44 (0) 20 3650 3650 
 Bob Pountney (Corporate Broking)           +44 (0) 20 3650 3652 
 IFC Advisory Limited 
 Tim Metcalfe                               +44 (0) 20 3934 6630 
  Zach Cohen                                 nuformix@investor-focus.co.uk 
 

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.

For more information, please visit www.nuformix.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAFLFILLFIELIS

(END) Dow Jones Newswires

January 15, 2024 06:30 ET (11:30 GMT)

Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024

Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024